Fundz

TriGemX Bio closes a $94 million financing round co-led by The Column Group, TCGX, and Viking Global Investors to advance phase 3 trials for their migraine treatment elismetrep.

RECENTLY ACQUIREDOct 01, 2026

Amount Raised

$94 Million

Round Type

Venture

New YorkBiotechnologyHealth Care

Investors

Viking Global InvestorsThe Column GroupTcgx

Description

TriGemX Bio, a biotechnology company focused on migraine treatments, has announced the closing of a $94 million financing. The funding will support the clinical development of elismetrep, their lead program. The round was co-led by The Column Group, TCGX, and Viking Global Investors, with additional participation. This financing marks a significant step toward advancing their innovative treatment.

Quick answer

TriGemX Bio raised $94 Million in a funding round, dated October 1, 2026. Investors: Viking Global Investors, The Column Group and Tcgx. TriGemX Bio is based in New York, New York, United States.

How much did TriGemX Bio raise?
TriGemX Bio raised $94 Million in a funding round on October 1, 2026.
Who invested in TriGemX Bio?
Viking Global Investors, The Column Group and Tcgx are named as investors in this round.
What does TriGemX Bio do?
TriGemX Bio is a biotechnology company focused on developing a first-in-class medicine for the treatment of migraine.
Where is TriGemX Bio based and how big is it?
TriGemX Bio is based in New York, New York, United States.

Source: Fundz verified event record.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as TriGemX Bio that raised within 45 days of this round, from Fundz verified event records.

  • Yicura BioMed raised an undisclosed amount (Series B) on November 13, 2026.
  • Boston Medical Sciences raised $35M (Series B) on November 13, 2026.
  • Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
  • Orakl Oncology raised $34M (Series A) on November 12, 2026.
  • BioWraptor raised $1.5M (Pre-Seed) on November 12, 2026.
  • Skribe Medical raised $1.6M (Pre-Seed) on November 12, 2026.

Who to call at TriGemX Bio, and when

A new round usually means TriGemX Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day TriGemX Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TriGemX Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TriGemX Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TriGemX Bio

Location

New York, New York, United States

About

TriGemX Bio is a biotechnology company focused on developing a first-in-class medicine for the treatment of migraine. They are advancing the clinical development of their lead program, elismetrep, which is a novel, oral TRPM8 channel blocker.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TriGemX Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for TriGemX Bio's next move

See what Strategic adds

TriGemX Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.